1988•PubMedRequires access

Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men.

Domenic A. Ciraulo, JAMIE G. BARNHILL, David J. Greenblatt, Richard I. Shader, Ann Marie Ciraulo, M F Tarmey, Monica A. Molloy, Mary Ellen Foti

Open publisher page 71 citations

Abstract

The abuse liability of alprazolam was studied in 17 abstinent alcoholic and 12 control subjects. A single 1-mg oral dose of alprazolam was administered, and subjective effects were measured by scales modified from the Addiction Research Center Inventory (ARCI). Multiple blood samples for alprazolam measurement were drawn over 48 hours. No statistically significant differences in pharmacokinetic parameters were found between groups. Alcoholics had lower baseline scores on the ARCI-Morphine/Benzedrine Group Scale (euphoria) and had greater drug-induced changes than nonalcoholics. The findings suggest that alcoholics may be at high risk to abuse alprazolam because it has a positive mood effect not seen in nonalcoholics.

About this research paper

What this paper is about

The abuse liability of alprazolam was studied in 17 abstinent alcoholic and 12 control subjects. A single 1-mg oral dose of alprazolam was administered, and subjective effects were measured by scales modified from the Addiction Research Center Inventory (ARCI). Multiple blood samples for alprazolam measurement were drawn over 48 hours. No statistically significant differences in pharmacokinetic parameters were found between groups. Alcoholics had lower baseline scores on the ARCI-Morphine/Benzedrine Group Scale (euphoria) and had greater drug-induced changes than nonalcoholics. The findings suggest that alcoholics may be at high risk to abuse alprazolam because it has a positive mood effect not seen in nonalcoholics.

Why it matters

OpenAlex reports 71 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The abuse liability of alprazolam was studied in 17 abstinent alcoholic and 12 control subjects. A single 1-mg oral dose of alprazolam was administered, and subjective effects were measured by scales modified from the Addiction Research Center Inventory (ARCI). Multiple blood samples for alprazolam measurement were drawn over 48 hours. No statistically significant differences in pharmacokinetic parameters were found between groups. Alcoholics had lower baseline scores on the ARCI-Morphine/Benzedrine Group Scale (euphoria) and had greater drug-induced changes than nonalcoholics. The findings suggest that alcoholics may be at high risk to abuse alprazolam because it has a positive mood effect not seen in nonalcoholics.

Key concepts: Alprazolam, Euphoriant, Mood, Addiction, Medicine, Psychology, Pharmacokinetics, Psychiatry

Related papers

Back to paper searchBrowse research topicsOriginal source
Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men. — Research Paper | ScholarLens